Local Institution
Vandœuvre-lès-Nancy 54511
0 studies enrolling now · 31 studies all time
What they study most
Advanced Cutaneous Melanoma, Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Bladder Cancer, Breast Cancer, Chronic Hepatitis B, Chronic Phase Chronic Myeloid Leukemia, Colitis, Ulcerative, Congestive Heart Failure, Crohn's Disease, Hepatitis C, Hepatitis C Infection, Hepatitis C Virus
Studies at this site
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) — Completed
- Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma — Completed
- Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia — Completed
- Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone — Completed
- Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
- Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma — Completed
- Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed
- Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment — Completed
- Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
- Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
- Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant — Completed
- Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus — Completed
- A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia — Completed
- Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) — Completed
- Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib — Completed
- First Line Hepato Cellular Carcinoma (HCC) — Completed
- Dasatinib in Combination With Revlimid (and Dexamethasone) — Completed
- A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies — Completed
- Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials — Completed
- First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy — Completed
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
- Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) — Completed
- Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease — Completed
- Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
- Phase II, 2nd Line Melanoma - RAND Monotherapy — Completed
- Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin — Completed
- Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed
- Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis — Completed
- Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed
- Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma — Completed